Pancreatic adenosquamous carcinoma

Summary

Pancreatic adenosquamous carcinoma (MONDO:0005614) is a cancer and 8 clinical trials. Top therapeutic interventions include leucovorin, domvanalimab, and zimberelimab. A subtype of adenosquamous carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pancreatic adenosquamous carcinoma
Mondo ID	MONDO:0005614
EFO	EFO:0006732
DOID	DOID:5637
NCIT	C5721
UMLS	C1335299
MedGen	277489
GARD	0024211
Anatomy (UBERON)	UBERON:0001264
Is cancer (heuristic)	yes

Also known as: adenosquamous carcinoma of pancreas · adenosquamous carcinoma of the pancreas · adenosquamous pancreas carcinoma · PAASC · pancreas adenosquamous carcinoma · pancreatic adenoacanthoma · pancreatic adenosquamous cancer · pancreatic adenosquamous carcinoma · pancreatic mixed squamous and adenocarcinoma · pancreatic mucoepidermoid carcinoma

Data availability: 20 cell lines.

Disease family

This is a subtype of adenosquamous carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › adenosquamous carcinoma › pancreatic adenosquamous carcinoma

Related subtypes (14): adenosquamous breast carcinoma, esophageal adenosquamous carcinoma, thymic adenosquamous carcinoma, Bartholin gland adenosquamous carcinoma, endometrial adenosquamous carcinoma, adenosquamous prostate carcinoma, adenosquamous lung carcinoma, gastric adenosquamous carcinoma, cervical adenosquamous carcinoma, colorectal adenosquamous carcinoma, gallbladder adenosquamous carcinoma, salivary gland adenosquamous carcinoma, liver adenosquamous carcinoma, skin adenosquamous carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	2
PHASE2	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04340141	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT06115499	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
NCT07491445	PHASE3	RECRUITING	Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT04858334	PHASE2	RECRUITING	APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04896073	PHASE2	COMPLETED	Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
NCT05419479	PHASE1/PHASE2	SUSPENDED	Switch Maintenance in Pancreatic
NCT04157127	PHASE1	RECRUITING	Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
NCT07573215	Not specified	AVAILABLE	Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LEUCOVORIN	4	1
DOMVANALIMAB	3	1
ZIMBERELIMAB	3	1
MINNELIDE	2	1
SOTIGALIMAB	2	1
CHEMBL541887	0	1
CHEMBL454299	0	1